BridgeMD
Compares treatment options for Pancreatic Cancer
Official title Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)
ClinicalTrials.gov ID: NCT05784311
What this study is testing
What is Cefuroxime?
Cefuroxime is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for pancreatic cancer.
Also referred to as Zinacef.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this multicenter randomized controlled trial is to evaluate the additional value of pre-emptive antibiotic treatment on clinically relevant organ/space surgical site infections (OSIs) in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile. The main objectives it aims to answer are: To evaluate the effect of pre-emptive antibiotic prophylaxis on clinically relevant OSIs in patients undergoing pancreatoduodenectomy with a high risk for contaminated bile To evaluate the effect of pre-emptive antibiotic prophylaxis on other postoperative outcomes (e.g.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 90
You may be able to join if
- Patients undergoing elective pancreatoduodenectomy with a high risk for contaminated bile defined as patients with preoperative biliary drainage or...
- Age \>18 years
You likely can't join if
- Pregnancy
- Contraindication for the study antibiotics (e.g. allergy or intolerance)
- Preoperative planned therapeutic antibiotic treatment (i.e. for cholangitis or liver abscesses)
- A reduced renal function, defined as an eGFR of \<60 ml/min/1.73m2 measured on the closest timepoint prior to pancreatoduodenectomy
The study team makes the final eligibility decision.
Where it's taking place
- Leiden, South Holland, Netherlands
- 's-Hertogenbosch, Netherlands
- Amsterdam, Netherlands
- Breda, Netherlands
- Eindhoven, Netherlands
- Enschede, Netherlands
- Groningen, Netherlands
- Maastricht, Netherlands
- Nijmegen, Netherlands
- Rotterdam, Netherlands
- Utrecht, Netherlands
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 90 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Leiden, South Holland, Netherlands; 's-Hertogenbosch, Netherlands; Amsterdam, Netherlands; Breda, Netherlands; Eindhoven, Netherlands; Enschede, Netherlands and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.